Clinical Trial

Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The standard and most common therapy is anticoagulation with heparin according to activated partial thromboplastin time (aPTT) during extracorporeal membrane oxygenation (ECMO) support. The study will focus on evaluating the efficacy and safety of new anticoagulants on ECMO, namely argatroban and enoxaparin in lower doses controlled according to targeted antiIIa and antiXa markers.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-24.
Trial Details
NCT Number NCT07499037
Lead Sponsor University Hospital Ostrava
Collaborators: University Hospital, Motol
Conditions Pneumonia, Heart Failure
Enrollment 200 participants
Start Date 2027-01
Primary Completion 2029-09 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-02